Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429646 | 0.88 | CYP2C9 (0.57) | ATMMEN1KMT2ACYP2C9HIF1A | |
| SCHEMBL7838089 | 0.86 | MEN1 (0.48) | ATMMEN1KMT2ACYP2C9HIF1A | |
| SCHEMBL29071977 | 0.85 | L3MBTL1 (0.59) | MEN1KMT2AL3MBTL1CNR2KDM4E | |
| SCHEMBL13486908 | 0.83 | MEN1 (0.49) | ATMMEN1KMT2ACYP2C9HIF1A | |
| SCHEMBL3238496 | 0.82 | GABRA1 (0.57) | LMNAHTT | |
| SCHEMBL31116611 | 0.82 | CA1 (0.61) | MEN1KMT2AL3MBTL1IDO1KDM4E | |
| SCHEMBL357145 | 0.82 | CA1 (0.61) | MEN1KMT2AL3MBTL1IDO1KDM4E | |
| SCHEMBL11673960 | 0.82 | ALOX5 (0.54) | ATMMEN1KMT2ACYP2C9HIF1A | |
| SCHEMBL17187879 | 0.82 | CYP2C9 (0.47) | ATMMEN1KMT2ACYP2C9HIF1A | |
| SCHEMBL2986215 | 0.82 | TAAR1 (0.50) | ATMMEN1KMT2ACYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1722779-A4 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | UNIV NORTH CAROLINA (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1722779-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005087225-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | BRCA1, CYP19A1, HUNK | ATM 784/4885MEN1 2665/4885KMT2A 4270/4885 |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | BRCA1, CYP19A1, CYP51A1 | ATM 991/4885MEN1 2932/4885KMT2A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.